BP
NMRA icon

Ballentine Partners’s Neumora Therapeutics NMRA Stock Holding History

Ballentine Partners’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,441
Closed -$178K – 933
2024
Q3 		$178K Buy
+13,441
New +$157K ﹤0.01% 763

Other funds holding NMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Ballentine Partners's NMRA Position: Q4 2024 in Review

Ballentine Partners sold out of Neumora Therapeutics (NMRA) in Q4 2024, closing a stake of 13,441 shares — an estimated $178K sold.

Ballentine Partners first reported a position in NMRA in Q3 2024 and held it in 1 quarter. The position peaked at $178K in Q3 2024. 134 funds tracked by Wall St. Rank hold NMRA as of Q4 2024.

  • Ballentine Partners reported no remaining Neumora Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Ballentine Partners sold 13,441 Neumora Therapeutics shares in Q4 2024, an estimated $178K.
  • Ballentine Partners first reported a position in Neumora Therapeutics in Q3 2024 and held it in 1 quarter.
  • Ballentine Partners's Neumora Therapeutics position peaked at $178K in Q3 2024.
  • 134 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2024.

Based on Ballentine Partners's 13F filing for Q4 2024, filed 16 Jan 2025.